Aaron Berger, MD

Aaron Berger, MD

Talks by Aaron Berger, MD

Urologist Led Advanced Prostate Cancer Practice Tips, Tricks and Pitfalls

Urologist Led Advanced Prostate Cancer Practice Tips, Tricks and Pitfalls

Posted by | Dec 2024

Aaron Berger, MD, delivers an in-depth discussion on the evolution and importance of urology-led advanced prostate cancer practices. In this 21-minute presentation, Dr. Berger traces the transformation of urological management from limited ADT to a multidisciplinary and pathway-driven approach today. Berger highlights the pivotal moments, such as the introduction of immunotherapy, effective oral options, and advancements in imaging guidelines, which allowed urologists to retain and expand their roles in treating advanced prostate cancer. He emphasizes the establishment of specialized clinics as critical, enabling comprehensive care through navigation systems, in-office dispensaries, and dedicated teams. Collaboration with radiation and medical oncologists is vital for managing complex cases and adopting innovations like PSMA-based therapies and triple therapy.

Read More
Optimal Management of Biochemically Recurrent Nonmetastatic Prostate Cancer

Optimal Management of Biochemically Recurrent Nonmetastatic Prostate Cancer

Posted by | Dec 2024

Aaron Berger, MD, delves into the evolving landscape of non-metastatic castration-sensitive prostate cancer (nmCSPC) and high-risk biochemical recurrence, focusing on diagnostic and therapeutic updates. In this 7-minute presentation, Dr. Berger emphasizes advanced imaging, particularly PSMA PET scans, as the diagnostic standard due to its superior sensitivity over conventional CT and bone scans.

Dr. Berger discusses treatment strategies, including salvage radiation therapy and the use of androgen deprivation therapy (ADT). For radiation-treated patients, focal salvage therapies, including cryoablation, HIFU, and electroporation, are discussed as options. The presentation underscores the shrinking non-metastatic space due to advancements in imaging technology that now frequently identify micrometastases.

Dr. Berger reinforces the importance of genetic testing and surveillance protocols involving regular PSA monitoring and imaging triggered by symptoms or PSA progression. He highlights the dynamic shifts in prostate cancer management, driven by improved diagnostics and the integration of advanced systemic therapies within an increasingly precise treatment paradigm.

Read More

Join the GRU Community

- Why Join? -